StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 
 
 
Novo Nordisk A/S Com
123.49
+0.03%
 

NVO

 

Novo Nordisk A/S Com

$ 123.49

 
+$0.04 | +0.03%
 
 
Open
$ 123.20
 
 
MKT CAP
$ 423.62B
 
High
$ 124.17
 
 
VOL
$ 3.98M
 
Low
$ 122.79
 
 
AVG VOL
$ 5.01M
 
 
 

Latest Updates

 
 
AlertEagle
 
AlertEagle  Yesterday at 08:48
 

$NVO Update: Zealand Pharma, a rival to Novo Nordisk and Eli Lilly, has seen its shares soar by 26-32% after promising results from a Phase 2 trial of its weight-loss drug. The drug is believed to have potential in treating both liver disease and obesity. 📈💉

 
 
 
  •  
  •  
  •   Like
  •  
     
     
     
     
     

    NVO Stock Analysis

      Login to display Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
     
     

    NVO Total Score

     

    Chart

     
     

    107.16

    103.87

    102.14

    143.55

     
     
    1month
    3month
    6month
    1year
     
    Total Return
    NVO
    vs.
    S&P500
     

     
    1-week Return
    +1.68%
     
    +1.89%
     
     
    5-week Return
    +15.45%
     
    +4.75%
     
     
    10-week Return
    +28.35%
     
    +9.17%
     
     
     
     

    Strengths

    NVO Rewards

     Trading below its fair value

    NVO Rewards

     Insider buying over the past 3 months

     

    Risk Analysis

    NVO Risk Analysis

     Earnings are forecast to decrease

    NVO Risk Analysis

     Investors losing their confidence

     
     

    NVO Risk Level

    This Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

     
    NVO Risk Level
    LOW
    HIGH

    Risk Volatility

     

    NVO has Low Risk Level

    Click here to check what is your level of risk

     

    NVO Analysts Opinion

    The company overall standing based on key factors, offering insights into analysts perspectives and market expectations. Hover over the category for more information

     
     

    Earnings

    ×
     

    Earnings

    4.00
     

    NVO Earnings Sentiment

     Above analyst estimates

    NVO Earnings Sentiment

     Reported a strong earnings

    NVO Earnings Sentiment

     Earnings increase YoY

     
     

    Rating

    ×
     

    Rating

    NA
     
     

    Momentum

    ×
     

    Momentum

    3.80
     

    NVO Momentum Analysis

     Has been gaining momentum

     

    Activity

    ×
     

    Activity

    3.84
     

    NVO Activity Sentiment

     Investors losing their confidence

    NVO Activity Sentiment

     Insider buying over the past 3 months

     

    Future

    ×
     

    Future

    2.95
     

    NVO Future Sentiment

     Earnings are forecast to decrease

    NVO Future Sentiment

     Trading below its fair value

     
     

    NVO Analysts Opinion

    NVO Analysts opinion is negative and it remained unchanged from the past 3 months

     

    NVO Street Consensus

    Analysts perspectives on the stock desirability, trend direction, and growth potential.

     
    85%
    Buy
    Opinion
    Trend
    Score
    Potential
    Score
     
     
    NA
    80%
    60%
     
    On Track
    On Track
    On Track
     

    NVO Street Opinion 

    NVO Street view is extremely ish but have mixed views on the near-term outlook

     

    NVO Performance Sentiment

    Sentiments overview associated with the company events and the stock performance.
     
    Very Bullish
    Bullish
    Neutral
    Bearish
    Very Bearish
     
    Positive vs Negative
    Contrasts the positive and negative sentiments surrounding the company performance.
     
    85%
    12%
    Positive
    Negative
    94 out of 111
    events present
    13 out of 111
    events present
     
     

    NVO Earnings

    The Trailing Twelve Months (TTM) reflects 12-month period, providing rview of NVO financial performance.

     
    Millions of Dollars
    TTM
    2022
    2021
    CAGR
     

     
    Total Revenue
    201,325
    176,954
    140,800
    +19.58%
     
     
    Cost of Revenue
    31,500
    28,448
    23,658
    +15.39%
     
     
    Gross Profit
    169,825
    148,506
    117,142
    +20.40%
     
     
    Operating Expense
    83,659
    73,697
    58,498
    +19.59%
     
     
    Operating Income
    86,166
    74,809
    58,644
    +21.21%
     
     
    Net Interest Income
    2,600
    -320
    436
    +144.20%
     
     
    Interest Expense
    -3,837
    378
    2,451
     
     
    Interest Income
    -1,056
    239
    2,887
     
     
    Other Income
    -
    -5,427
    616
    -
     
     
    EPS
    -
    24.51
    20.79
    -
     
     
    Similar to NVO
    Total Score
    Close Price
    %
    Change

    AMGN

    Amgen

    2.90

    286.37

    -0.97%

     
     
     
    Highlights
    Last Modify
    Price
    % Change

     
    Stock Buyback
    Today
    123.49
    +0.03%
     
    New Product
    This Week
    124.52
    +2.97%
     
    Investors Selling
    1 Week Ago
    123.29
    +2.75%
     
    Concerns
    1 Week Ago
    120.53
    -0.55%
     
    Concerns
    2 Weeks Ago
    118.39
    -0.23%
     
     

    NVO Latest News Feed
































     
     
     
    joker
     
     
     
    StocksRunner

    Explore our NVO Stock insights

    • In-Depth Market Analysis and Trends
    • Expert Insights on Market Dynamics
    • Tailored FDX Stock Strategies
    • Effective Risk Management
     

    FIND US ON

    StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
     

    Receive our NVO Daily Alerts

    Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

     
    Market Trends

    Stay ahead of the market

    Market trends

    Investment tips

    Market analysis service

     
    Investment Insights

    Future potential

    Informed investment decisions

    Investment analysis

    IInvestment strategies

     
    Stock Analysis

    In-depth stock analysis

    Performance analysis

    Stock market insights

    Financial trends analysis

     
    About StocksRunner

    Log In

    Sign Up

    Contact Us

    Terms of use

    Privacy Policy

     
     

    Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

    Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

    This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

     
     
    StocksRunner logo

    StocksRunner

    Get the pulse of the market

     
    StocksRunner
     
     
     
     

    Stock Insights

     
     
     
     

    Strengths

     

    NVO Rewards

     Trading below its fair value

    NVO Rewards

     Insider buying over the past 3 months

     

    Risk Analysis

     

    NVO Risk Analysis

     Earnings are forecast to decrease

    NVO Risk Analysis

     Investors losing their confidence

     
     
     

    NVO Risk Level

     
     
     

    The Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

     
     
    NVO Risk Level
    LOW
    HIGH

    Risk Volatility

     

    NVO has Low Risk Level. Click here to check what is your level of risk

     
     
     
     

    Stock Analysis

     
     
     
     

    NVO

     

    Novo Nordisk A/S Com

    $ 123.49

     
    +$0.04 | +0.03%
     
     
      Overview  
     
      Chart  
     
      Earnings  
     
      Sentiment  
     
      News  
     
      Updates  
     

     
    joker
     
     
     
    Open
    $ 123.20
     
     
    MKT CAP
    $ 423.62B
     
    High
    $ 124.17
     
     
    VOL
    $ 3.98M
     
    Low
    $ 122.79
     
     
    AVG VOL
    $ 5.01M
     
     
     

    Latest Updates

     
     
     
    AlertEagle
     
    AlertEagle  AlertEagle
     
      
     

    Followers

    214

    Following

    11

     
     
     

    AlertEagle, our Content Editor, specializes in delivering swift and concise stock market alerts. With a focus on timely updates, they keep our audience informed about crucial developments, empowering traders and investors to make informed decisions in the fast-paced financial landscape. Stay ahead with AlertMaster's curated content for a real-time grasp of market trends and opportunities.

     
     
    AlertEagle  Yesterday at 08:48
     

    $NVO Update: Zealand Pharma, a rival to Novo Nordisk and Eli Lilly, has seen its shares soar by 26-32% after promising results from a Phase 2 trial of its weight-loss drug. The drug is believed to have potential in treating both liver disease and obesity. 📈💉

     
     
     
  •  
  •  
  •   Like
  •  
     
     
     
     
     

    NVO Analysis

      Sign in to view Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
     
     

    Chart

     
     

    107.16

    103.87

    102.14

    143.55

     
     
    1month
    3month
    6month
    1year
     
    Total Return
    NVO
    vs.
    S&P500
     

     
    1-week Return
    +1.68%
     
    +1.89%
     
     
    5-week Return
    +15.45%
     
    +4.75%
     
     
    10-week Return
    +28.35%
     
    +9.17%
     
     
     

    NVO Analysts Opinion

    Overall standing by considering key factors, reflecting analysts perspectives and market expectations. Hover over the category for more information

     
     

    Earnings

    ×
     

    Earnings

    4.00
     

    NVO Earnings Sentiment

     Above analyst estimates

    NVO Earnings Sentiment

     Reported a strong earnings

    NVO Earnings Sentiment

     Earnings increase YoY

     
     

    Rating

    ×
     

    Rating

    NA
     
     

    Momentum

    ×
     

    Momentum

    3.80
     

    NVO Momentum Sentiment

     Has been gaining momentum

     

    Activity

    ×
     

    Activity

    3.84
     

    NVO Activity Sentiment

     Investors losing their confidence

    NVO Activity Sentiment

     Insider buying over the past 3 months

     

    Future

    ×
     

    Future

    2.95
     

    NVO Future Sentiment

     Earnings are forecast to decrease

    NVO Future Sentiment

     Trading below its fair value

     
     

    NVO Analysts Opinion

    NVO Analysts opinion is negative and it remained unchanged from the past 3 months

     

    NVO Street Consensus

    Analysts perspectives on the stock desirability, trend direction, and growth potential.

     
    85%
    Buy
    Opinion
    Trend
    Score
    Potential
    Score
     
     
    NA
    80%
    60%
     
    On Track
    On Track
    On Track
     

    NVO Street Opinion 

    NVO Street view is extremely ish but have mixed views on the near-term outlook

     
    NVO Performance Sentiment
    Sentiments overview associated with the company events and the stock performance.
     
    Very Bullish
    Bullish
    Neutral
    Bearish
    Very Bearish
     
    Positive vs Negative
    Contrasts the positive and negative sentiments surrounding the company performance.
     
    85%
    12%
    Positive
    Negative
    94 out of 111
    events present
    13 out of 111
    events present
     

     

    NVO Earnings

    The Trailing Twelve Months (TTM) data reflects the most recent 12-month period, providing overview of NVO financial performance.

     
    Millions of Dollars
    TTM
    2022
    2021
    CAGR
     

     
    Total Revenue
    201,325
    176,954
    140,800
    +19.58%
     
     
    Cost of Revenue
    31,500
    28,448
    23,658
    +15.39%
     
     
    Gross Profit
    169,825
    148,506
    117,142
    +20.40%
     
     
    Operating Expense
    83,659
    73,697
    58,498
    +19.59%
     
     
    Operating Income
    86,166
    74,809
    58,644
    +21.21%
     
     
    Net Interest Income
    2,600
    -320
    436
    +144.20%
     
     
    Interest Expense
    -3,837
    378
    2,451
     
     
    Interest Income
    -1,056
    239
    2,887
     
     
    Other Income
    -
    -5,427
    616
    -
     
     
    EPS
    -
    24.51
    20.79
    -
     
     
    Highlights
    Last Modify
    Price
    % Change

     
    Stock Buyback
    Today
    123.49
    +0.03%
     
    New Product
    This Week
    124.52
    +2.97%
     
    Investors Selling
    1 Week Ago
    123.29
    +2.75%
     
    Concerns
    1 Week Ago
    120.53
    -0.55%
     
    Concerns
    2 Weeks Ago
    118.39
    -0.23%
     
     
    NVO Latest News Feed

    Novo Nordisk A/S - share repurchase programme.

    Today

    Activity

    Heres 1 Pharmaceutical Stock That Looks Unstoppable. Hint: Its Not Novo Nordisk..

    Thu Feb 22, 2024

    Potential

    Heres 1 Pharmaceutical Stock That Looks Unstoppable. Hint: Its Not Novo Nordisk. Diabetes and obesity medications are becoming wildly popular. Commercials for them dominate the airwaves on a daily basis -- many produced by Novo Nordisk. This Danish pharma

    Thu Feb 22, 2024

    Potential

    India pharma companies develop versions of Wegovy to get in on weight-loss windfall. Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie both at home and abroad have begun developing their own versions of N

    Thu Feb 22, 2024

    Activity

    Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term. Taking full advantage of the stock market and investing with confidence are common goals for new and old investors and Zacks Prem

    Wed Feb 21, 2024

    Potential

    7 Analysts Assess Novo Nordisk: What You Need To Know. In the last three months 7 analysts have published ratings on Novo Nordisk (NYSE:) offering a diverse range of perspectives from ish to bearish. The table below summarizes their recent ratings showca

    Tue Feb 20, 2024

    Activity
    Potential

    Novo Nordisk A/S – Share repurchase programme. Bagsværd Denmark 19 February 2024 – On 6 February 2024 Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 A

    Mon Feb 19, 2024

    Activity

    Novo Nordisk Unusual Options Activity For February 14. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for Novo Nordisk (NYSE:) we detected 21 trades. If we consider the specifics of each trade i

    Wed Feb 14, 2024

    Activity
    Momentum
    Potential

    1 Potential Catalyst That Could Light a Fire Under Novo Nordisks Stock This Year. Novo Nordisk (NYSE: NVO) is trading at a 52-week high. At 45 times trailing earnings shares of the Danish drugmaker may look expensive to many investors. But despi

    Wed Feb 14, 2024

    Momentum

    Exploring The Competitive Space: Merck &. Co Versus Industry Peers In Pharmaceuticals. In today'.s rapidly changing and fiercely competitive business landscape it is essential for investors and industry enthusiasts to thoroughly analyze companies.

    Wed Feb 14, 2024

    Activity

    Novo Nordisks Weight Loss Drugs Ozempic Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement. Preliminary findings presented at an orthopedic surgeons’. meeting on Monday indicate that new drugs designed for diabetes and weight loss c

    Mon Feb 12, 2024

    Activity
    Activity
    Potential

    Why Novo Nordisk (NVO) is a Top Stock for the Long-Term. Here at Zacks we offer our members many different opportunities to take full advantage of the stock market as well as how to invest in w

    Mon Feb 12, 2024

    Activity
    Potential

    Novo Nordisks controlling shareholder plans to invest up to $7 bln a year by 2030 - FT. Novo Holdings the controlling shareholder of Danish obesity drugmaker Novo Nordisk plans to invest up to $7 billion annually by 2030 the Financial Times repo

    Mon Feb 12, 2024

    Activity

    Dont Worry About Novo Nordisks Premium Stock Price. Its Still a Buy.. If you arent familiar with Novo Nordisk (NYSE: NVO) by name youll probably recognize some of its flagship medications. The Danish pharmaceutical giant is the developer of diab

    Sun Feb 11, 2024

    Potential
    Potential

    makers of ozempic mounjaro race to meet demand for weight-loss drugs. last year many people who wanted to start taking the weight-loss drug wegovy were turned away because of a shortage of the medication. for patients that has spelled frustration. for nov

    Thu Feb 8, 2024

    Activity

    novo nordisk stock is a big money favorite. institutional volumes reveal plenty. for 1-year nvo has enjoyed heavy institutional support. each green bar signals unusually large volumes in nvo shares pushing the stock higher: plenty of health care names are

    Thu Feb 8, 2024

    Momentum

    novo nordisk ceo wins 13% raise amid soaring demand for weight loss drugs.

    Wed Feb 7, 2024

    Momentum

    catalent (ctlt) rides on acquisition offer from novo holdings. catalent&rsquo.s ctlt shares rose 7.2% so far this week. the company&rsquo.s share price surged following the announcement of its

    Wed Feb 7, 2024

    Activity
    Momentum

    why novo nordisk stock crushed the market on monday. a major acquisition by its controlling shareholder pushed novo nordisks (nyse: nvo) United States-listed shares 4% higher on monday. as a result of the deal novo nordisk will acquire from that

    Mon Feb 5, 2024

    Activity
    Momentum

    novo nordisk drops $11 billion to expand weight-loss drug production. its bulking season at novo nordisk. on monday the danish pharma firm behind wegovy and ozempic announced an $11 billion deal to significantly expand production capacity for its blockbus

    Mon Feb 5, 2024

    Activity

    novo nordisk buys manufacturing power as it seeks to ramp up wegovy. after struggling to keep up with patient demand for its weight-loss wonder drug wegovy novo nordisk said monday that it is buying more manufacturing capacity. novo holdings the danish dr

    Mon Feb 5, 2024

    Activity

    novo nordisk (nvo) to acquire 3 catalent sites for $11b. novo nordisk nvo announced that it will acquire three manufacturing sites from novo holdings a/s for an upfront payment of $11 billion t

    Mon Feb 5, 2024

    Activity

    m & a news: novo nordisk announces $16.5b catalent (nyse:ctlt) deal shares surge - tipranks.com. danish pharmaceutical company novo nordisk (nyse:nvo) announced that its controlling shareholder novo holdings will acquire global contract development and ma

    Mon Feb 5, 2024

    Activity

    novo nordisk parent buys us drug firm for $16.5bn to expand wegovy supply. the explosion in demand for the weight-loss drug wegovy has led to the holding company behind its maker novo nordisk buying a leading us-based drugmaker for $16.5bn (£13.2bn) to in

    Mon Feb 5, 2024

    Activity

    novo nordisk strikes $11bn deal to expand production of weight loss drugs.

    Mon Feb 5, 2024

    Activity

    ozempic maker strikes $11b deal with catalent as it rushes to meet massive weight-loss drug demand. maker of miracle weight loss drugs ozempic and wegovy novo nordisk a/s nvo has announced the acquisition of three fill-finish sites from novo holdings a/s

    Mon Feb 5, 2024

    Activity

    fill-finish sites will help novo nordisk boost wegovy ozempic output. novo nordisk'.s acquisition of three fill-finish sites will help boost output of its popular wegovy and ozempic drugs the ceo of its parent company novo holdings said on monday. "

    Mon Feb 5, 2024

    Activity

    novo nordisk to acquire three fill-finish sites from novo holdings a/s in connection with the catalent inc. transaction.

    Mon Feb 5, 2024

    Activity

    its shaping up to be a great quarter for europes biggest companies. fourth-quarter earnings season in europe is still in its early days but the largest companies on the continent are mostly hitting their stride. novo nordisk nvo the maker of wildly popul

    Mon Feb 5, 2024

    Earnings

    novo nordisk - adr shares climb 6.2% past previous 52-week high - market mover. novo nordisk - adr (nvo) shares closed 6.2% higher than its previous 52 week high giving the company a market cap of $374b. the stock is currently up 5.4% year-to-da

    Thu Feb 1, 2024

    Momentum

     
     
     
     
     

    Score Tracker

     
     
     
    Based on 111 events in the last 90 days from financial news and social media. Last updated Feb 26, 2024 23:13 Wall St. time
     
     

    NVO Total Score

     
     
     
     
     

    Similar to NVO

     
     
     
    Symbol
    Score
    % Change

    AMGN

    Amgen

    2.90

    -0.97%

    286.37

     
     
     
     
     
     
    StocksRunner

    Discover NVO Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of NVO. We're here to help you make informed investment decisions today.

     

    FIND US ON

    StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

     

    Receive our NVO Daily Alerts

    Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

     
    Market trends

    In-depth stock analysis

    Informed investment decisions

    Stock market insights

    Stock trading tips

    Stock analysis

    NVO Stock trends

    NVO Stock performance

    NVO Stock analysis

    NVO investment strategies

    Stock strategies

    Trading strategies

    StocksRunner updates

    StocksRunner ideas

    Financial Reports

     
     

    Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

    Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

    This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

     
     
     
    Post ×
     
    0/666
    joker